Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction

Laboratory resurrection of ancient coagulation factor IX (FIX) variants generated through ancestral sequence reconstruction (ASR) led to the discovery of a FIX variant, designated An96, that possesses enhanced specific activity independent of, and additive to that provided by human p.Arg384Lys, referred to as FIX-Padua.The goal of the current study was to identify the amino acid substitution(s) responsible for the enhanced activity of An96 and create a humanized An96 FIX transgene for gene therapy application.Reductionist screening approaches, including domain swapping and scanning residue substitution, were employed and guided by one-stage FIX activity (OSA) assays. In vitro characterization of top candidates included recombinant high purity preparation, specific activity determination and enzyme kinetic analysis. Final candidates were packaged into adeno-associated viral (AAV) vectors and delivered to hemophilia B mice.Five of 42 total amino acid substitutions in An96 appear sufficient to retain the enhanced activity of An96 in an otherwise human FIX variant. Additional substitution of the Padua variant further increases the specific activity 5-fold. This candidate, designated ET9, demonstrates 51-fold greater specific activity than hFIX. AAV2/8-ET9 treated hemophilia B mice produced plasma FIX activities equivalent to those observed previously for AAV2/8-An96-Padua, which were 10-fold higher than AAV2/8-hFIX-Padua.Starting from computationally inferred ancient FIX sequences, novel amino acid substitutions conferring activity enhancement were identified and translated into an AAV-FIX gene therapy cassette demonstrating high potency. This ASR discovery and sequence mapping refinement approach represents a promising platform for broader protein drug and gene therapy candidate optimization.